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Osteochondral lesions of the talus (OLTs) are a common complication following trauma, involving both
the articular cartilage and the underlying subchondral bone, with variable aetiologies and often pre-
senting with non-specific symptoms. Diagnosis of OLTs requires a combination of clinical assessment and
imaging and despite many different treatment options, there is no generalised consensus regarding
which option is the most effective. Left untreated, OLTs risk progressing to osteoarthritis. Acute non-
displaced OLTs can be treated non-operatively. However, OLTs refractory to non-surgical care for three
to six months may be suitable for surgical care. In these cases, conservative treatments are often un-
successful, particularly for larger and more severe defects and so the majority require surgical inter-
vention. Although bone marrow stimulation techniques remain the “gold standard” for lesions
<150 mm2, there still requires a need for better long term clinical data and cost-benefit analyses
compared with other treatment options. Biological attempts at either regenerating or replacing the
articular cartilage are however demonstrating some promising results, but each with their own ad-
vantages and disadvantages. In this review, we summarise the clinical management of OLTs and present
the current concepts of different treatment regimes.
Crown Copyright © 2021 Published by Elsevier, a division of RELX India, Pvt. Ltd on behalf of
International Society for Knowledge for Surgeons on Arthroscopy and Arthroplasty. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Osteochondral lesions of the talus (OLTs), also known as talar
osteochondral defects, include many varieties of pathologies such
as osteochondritis dissecans, transchondral fractures and osteo-
chondral fractures. In general, OLTs refer to any defect of the ankle
articular cartilage and underlying subchondral bone.1 OLTs are
mainly associated with trauma, with the majority of defects
occurring in young people aged between 20 and 40 years, following
ankle sprains or fractures.2 They can be diagnosed by plain radi-
ography, computerized tomography (CT), magnetic resonance im-
aging (MRI) and arthroscopy; OLT classifications among these
diagnostic techniques also vary.3 Patients with symptomatic OLTs
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non-surgically with successful results in up to 50% of cases.4,5 Due
to the low healing capacity of articular cartilage, conservative
treatments such as immobilisation, rest and restriction of activities
do not have a good performance in ankle restoration in late stage
symptomatic OLT patients.6 Untreated OLTs may contribute to the
development of early-stage osteoarthritis (OA) and lead to the se-
vere disability.7,8 Bone marrow stimulation is still a gold standard
among surgical interventions for lesions <150mm2, but it cannot
promise good long-term results.1,9 Newer, novel cell-based thera-
pies are developing rapidly, aiming for safe, cost-effective and
improved long-term results.2. Aetiology
The aetiology of OLTs is still controversial but are more common
in young and active patients (20e40 years old) following an ankle
sprain or trauma.2,10 It is widely accepted that OLTs are caused by
both traumatic and nontraumatic events with up to 50% of ankle
sprains and over 70% of ankle fracture cases leading to thetd on behalf of International Society for Knowledge for Surgeons on Arthroscopy and
mons.org/licenses/by/4.0/).
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(2000),12 demonstrated 93% of patients with lateral lesions had a
history of trauma, compared to only 62% with medial lesions. Ac-
cording to Berndt and Harty,13 the mechanism of injury in lateral
lesions, is associated with ankle joint dorsiflexion and inversion,
while in medial lesions it is associated with ankle plantarflexion
and inversion. OLTs without trauma history could possibly be
caused by repetitive microtrauma, ischemia, subsequent avascular
necrosis, genetic predisposition and endocrine or metabolic
factors.14
Depending on their anatomical location, OLTs are divided into
different types. Posteromedial and anterolateral OLTs were tradi-
tionally thought to be the most common OLTs.13 Raikin et al. (2007)
examined 424 patients by MRI based on a 9-zone anatomic grid
system (Fig. 1), and found that the majority of lesions (53%) were
located in zone 4 (centromedial), and that the second most com-
mon lesion location was zone 6 (centrolateral).15 Another study,
however, demonstrated the opposite with regards symptomatic
and operatively treated lesions, with the centrolateral region being
twice as common as the centromedial region of the talar dome.16
Despite this, these studies demonstrate that the centrolateral and
centromedial areas of the talar dome are the most common loca-
tions for OLTs. In addition, it has been shown in several studies that
medial lesions are generally larger and deeper while lateral lesions
are smaller and shallower.13,15,16 However, lateral lesions tend to be
more symptomatic than medial lesions, possibly due to the higher
baseline contact pressure found in the centrolateral area compared
to the centromedial area of the ankle joint.16
It has been demonstrated that the posteromedial and antero-
lateral regions of the talar dome have the thickest articular carti-
lage, as evidenced by quantitative cartilage thickness
measurements of 12 cadaveric ankle joints by high resolution ste-
reophotography.17 The authors of this study have related this
finding to an adaptive response of the tissue in this region to theFig. 1. Anatomical 9 zone grid system of the talar dome.15 The talar dome is divided
into 9 equal zones, with zones 1, 2 and 3 located anteriorly and zones 3, 6 and 9 located
laterally.
232greatest mechanical stress, and claimed that these results are
consistent with the most common sites of OLTs.17 However, other
studies suggest that the posterolateral region of the talar dome has
the thickest articular cartilage and that the anterolateral region has
the thinnest articular cartilage, as assessed by confocal microscopy
and MR imaging with 3D modelling respectively.18,19 Further,
Sugimoto et al. (2005) concluded that articular cartilage in the
medial corner of the talar dome showed the greatest thickness,
while the lateral gutter of the talar dome showed the least thick-
ness, as assessed radiographically.20 Taken together, although there
is no complete agreement on the thickness of cartilage in specific
regions, the cartilage thickness has been shown to vary in all
studies across the talar dome, and its relationship with the mech-
anism of OLT development requires further investigation.
Compared to the knee, the ankle is anatomically different: it has
a smaller articular contact area than the knee, and over 60% of the
talar dome is covered by hyaline cartilage. Ankle cartilage has a
higher dynamic stiffness due to the higher proteoglycan content,
which contributes to stability when weightbearing or loading.21
The average cartilage thickness of the ankle is almost two folds
thinner than the knee, however a study showed that the ankle has a
relatively higher proportion of the superficial zone of cartilage,
which indicates that ankle has stronger protection than the knee
when weightbearing.22 In addition, ankle articular cartilage has
undetectable levels of matrix metalloproteinase-8 (MMP-8)
compared to knee articular cartilage, reducing endogenous degra-
dation of extracellular matrix proteins.23 From a biomechanical
point of view, the main movements of the ankle joint are rolling
and rotating, while the knee experiences higher shear forces from
its rolling, sliding and rotating movements.24 Although the devel-
opment of ankle OA is considered to be associated with untreated
OLTs,7,8 the incidence of OA in the ankle is relatively low; around
15% of adults are affected by OAworldwide, however, only 1% of this
is ankle OA.25 In a 21-year follow up study, Bauer et al. (1987) found
that only two out of 30 patients’ OLTs had progressed on to develop
OA.26 According to Günther et al. (1998), 67% of knee OA cases were
primary origin,27 while Valderrabano et al. (2008) reported that
primary ankle OA only accounts for 9% of cases, whilst 78% of OA
cases were posttraumatic.25 In conclusion, the ankle develops less
OA than the knee,28 with ankle OA developing mainly post-
traumatically and knee OA developing idiopathically.24
3. Diagnosis and evaluation
Pain, swelling and stiffness are the most common complaints of
presenting patients with OLTs, occurring particularly with high
levels of activity such as sport, but rarely present at rest.29 Occa-
sionally, there may also be mechanical symptoms present such as
locking and catching.3 Patients will often relate the pain experi-
enced to a history of either a single trauma or recurrent sprains.
Often the initial OLT is misdiagnosed as an ankle sprain.30 Chronic
OLTs present with non-specific symptoms, in these cases, physical
examination may show an effusion, decreased range of motion,
general tenderness, and pain with inversion or dorsiflexion.29 In
general, patients often describe a deep-seated pain with more
chronic OLTs compared with a more superficial pain with synovi-
tis.31 Of course, the absence of physical signs and symptoms on
examination does not exclude the presence of OLTs, highlighting
the importance of further clinical imaging investigations being
required to confirm OLT diagnosis.31
Imaging modalities most commonly utilised in the clinic for the
identification and diagnosis of OLTs include plain radiography, MRI
and CT, each with their own benefits, drawbacks and classification
systems (Table 1). Initially, plain radiographs are often used upon
first presentation usually taken in anterior-posterior (AP) mortise
Table 1
Overview of the classification systems used across the different assessment modalities used in the diagnosis of OLTs. OC ¼ osteochondral fragment; SCB ¼ subchondral bone.
X-Ray MRI CT Arthroscopy
Berndt and Harty13 Hepple34 Ferkel36 ICRS37 Cheng-Ferkel38
I e subchondral
compression
1 - articular damage only I - cystic lesion, intact overlying
articular cartilage
1 e superficial zone softening
or fissure
A e smooth and intact
cartilage, but soft
II e partially detached
OC fragments
2a e Articular cartilage damage with
subchondral fracture (- odema)
IIA e cystic lesion with articular
surface communication
2 e lesions extend <50% depth B e rough articular surface
III e fully detached OC
fragments
2b e Articular cartilage damage with
subchondral fracture (þodema)
IIB e overlying non-displaced OC
fragment
3 e lesions extend >50% depth
but not into SCB
C e fissures and
fibrillations present
IV e displaced OC
fragments
3 e detached non-displaced OC fragment III e non-displaced OC fragment
with lucency
4 e lesion extends into the SCB D e cartilage flap or
exposed SCB
4 e detached and displaced OC fragment IV e displaced OC fragment E  loose, non-displaced
fragments
5 e subchondral cysts F e displaced fragment
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injury a trauma series is often taken. Radiographs have relatively
low sensitivity and are often unclear, missing over 40% of cases.31,32
The Berndt and Harty radiography score is a 4-stage classification
system that assesses the initial subchondral compression (stage I)
and osteochondral fragments being either partially detached (stage
II), completely detached (stage III) or displaced (stage IV; Table 1).13
MRI is more able to clearly visualise soft tissues such as articular
cartilage, synovium and tendons, making it advantageous in
detecting and characterising OLTs.31 It is often the imaging mo-
dality of choice following inconclusive plain radiographs or
continuation of symptoms. However, MRI is less able to assess bony
changes and can make it difficult to fully assess the true status of
the subchondral bone and the exact lesion dimensions.33 OLTs on
MRI are classified according to the 5-stage Hepple MRI classifica-
tion system,34 where stage 1 is articular cartilage damage only,
stage 2 is cartilage damage with subchondral fracture (this is
further categorised as either acute (2a) or chronic (2b) dependent
upon the presence of oedema), stages 3 and 4 include detached
non-displaced and displaced osteochondral fragments, respectively
and stage 5 is the presence of subchondral cysts (Table 1).
CT on the other hand provides a far superior assessment of the
subchondral bone compared to MRI and can therefore more accu-
rately predict the depth of the OLT unless it is an early lesion, which
is characterised by changes in the articular cartilage.35 Performing a
CT scan can provide the surgeon with the finer details required for
accurate surgical planning.35 OLTs on CT are classified according to
the Ferkel systemwhere stage I is the presence of a cystic lesion but
with intact overlying articular cartilage,36 stage IIA is where the
cystic lesion communicates with the articular surface and stage IIB
includes an overlying non-displaced osteochondral fragment, stage
III is a non-displaced fragment with lucency beneath it and stage IV
is a displaced fragment (Table 1).
Arthroscopy is also an effective method for visualising and
investigating OLTs. The ability to assess the entire joint in addition
to probing the lesion can provide the most comprehensive evalu-
ation in deciding the most appropriate treatment regime. Arthro-
scopic evaluation of OLTs uses the International Cartilage Repair
System (ICRS) grading,37 which is a standardised grading system.
Grade 1 lesions involve the superficial zone with softening or
fissure, Grade 2 lesions extend less than 50% of the depth, Grade 3
greater than 50% in the depth but not to the subchondral bone as in
Grade 4 (Table 1). Cheng-Ferkel grading is another arthroscopic
grading system used in OLT evaluation, Grade A lesions present
smooth and intact cartilage with a soft or ballottable arthroscopic
appearance, Grade B lesions show a rough surface, Grade C lesions
appear fibrillations or fissures, Grade D lesions have a flap present
or bone exposed, Grade E lesions are loose and normally show non-
displaced fragments and displaced fragments present in Grade F233lesions (Table 1).38
4. Treatment and outcomes
The goal of any treatment strategy of course is to diminish
debilitating symptoms such as pain and swelling and to improve
function. The effectiveness of each strategy, however, is variable
and often the strategy adopted is based not only on the type and
size of the defect but also preferences of the treating clinician. In
acute non-displaced OLTs injuries conservative methods of treat-
ment are usually considered with the intention of reducing the load
on the damaged cartilage to resolve bone oedema or encourage
healing of any detached fragments.39 Methods include rest and/or
restriction of activities with or without the use of non-steroidal
anti-inflammatories (NSAIDs), short-term immobilisation in a cast
or boot for approximately 6 weeks, followed by physiotherapy and
progressive weight-bearing with a slow return to previous activ-
ities.1,29 Such conservative techniques are effective in only ~50% of
cases.39 Chronic symptomatic OLTs, acute fragmented OLTs and
those refractory to conservative management should be considered
for surgical intervention.1 Acute displaced, symptomatic OLTs can
be treated by open or arthroscopic methods, whereas large OLTs are
usually fixed using headless cannulated screws or absorbable pins.
Access to the ankle is restricted and thismay require either amedial
or lateral malleolar osteotomy for access. Small or fragmented le-
sions can simply be excised (Fig. 2). Symptomatic OLTs that are
chronic or refractory to non-surgical measures should be consid-
ered for surgical intervention. Surgical interventions to treat OLTs
are most commonly performed as arthroscopic interventions. The
majority of procedures treat the OLTs through debridement of any
damaged hyaline cartilage and underlying subchondral bone. The
‘gold standard’ treatment for lesions <150 mm2 remains micro-
fracture,1,9 which involves creating small holes in the subchondral
bone to create a new blood supply, also resulting in innate
mesenchymal stem or stromal cells (MSCs) entering the defect from
the subchondral blood/marrow and stimulating healing of the
cartilage. Microfracture benefits patients who require quick return
to function, as this procedure requires early mobilisation of the
joint through its’ associated recommended rehabilitation pro-
gramme.40 Optimal clinical improvements of microfracture (based
on Visual Analogue Scale (VAS) and American Orthopaedic Foot and
Ankle Society (AOFAS) score) have been demonstrated at 24
months post-operatively.41 Recently published findings from both
Kim et al. (2019) and Choi et al. (2020) indicate that microfracture
results in mid-term improvements.41,42 When assessing 70 pa-
tients, 85% of patients showed some improvement 6 months after
their microfracture, for whom their symptoms did not worsen from
baseline at 3 years post-operatively.41 Further, in a study of 156
patients (165 ankles) improvement or maintenance of pain and
Fig. 2. 22-year-old female case presenting with an acute injury, with a history of a fall from a horse. X-ray (A) and CT (BeC) imaging demonstrated lateral talar dome OLTs
(arrow). OLT fragment was excised arthroscopically (D).
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baseline scores could be demonstrated up to six years post-oper-
atively.42 There does appear to be an inverse relationship between
the size of the lesion and the outcome following microfracture. The
critical size of the defect appears to be those that are less than 150
mm2.41,43 Interestingly, a systematic review of 70 patients indicated
that microfracture might also be effective as a treatment for non-
primary OLTs.44
In patients where lesions are observed within the subchondral
bone but the hyaline cartilage is intact, retrograde drilling can be
offered with the aim of treating the subchondral lesion whilst
preserving overlying cartilage.45 In the retrograde drilling proced-
ure, articular cartilage is selected for entry into the talus and then a
guidewire is directed into the lesion in a retrograde direction under
x-ray control. This can also be under computer navigation to place
the guide wire and direct the location of drilling.45
Other interventions used to treat OLTs include those in which
osteochondral transplants are inserted into small defect. These can
be in the form of Osteochondral Autograft Transfers or Osteo-
chondral Allograft Transplantations (OATs). In either of these pro-
cedures, non-weight bearing cartilage and subchondral bone is
harvested as a cylindrical plug which is matched in size and area to
the problem defect. To treat larger defects, mosaicplasty can be
performed in which multiple smaller osteochondral (OC) plugs are
taken and inserted into the defect(s).46 For defects that are less than
1 cm2, OATs are more commonly used in which the OC plugs are
harvested from the patient themselves. Where defects are larger
than 2 cm2, OATs are carried out using arthrotomy. This relies on
the harvest of OC plugs from cadaveric donors and subsequent
sterilisation of the tissue prior to being transplanted into the pa-
tient’s defect site. OATs have long been turned to as a surgical op-
tion for the treatment of OLTs, with these surgeries having been
performed widely since 1992.47 A number of systematic reviews
have recently been published which aimed to determine the clin-
ical outcomes following OATs in the ankle.48 Pereira et al. (2021),
found that in 12 studies, yielding 191 patients, there were no short-
term complications following fresh OATs and that the graft survival
rate was 86.6% (assessed by AOFAS and VAS score).48 Autologous
osteochondral transplants were also concluded to have good clin-
ical outcomes (AOFAS, MRI and radiographs) at a mean of 62.8
months follow-up, although donor site morbidity was demon-
strated in 18 of the 500 study participants.49
More recently, surgeons have been investigating the potential of
another allogeneic tissue donor source which uses particulated
juvenile articular cartilage (PJAC).50 These juvenile grafts are taken
from donors typically younger than 13 years old. The only com-
mercial graft available for this procedure at present, is DeNovo NT
Natural Tissue Graft (Zimmer, Warsaw, IN, USA), marketed as a pre-
packaged allograft consisting of immature chondrocytes in their
innate extracellular matrix. These grafts can be used to treat focal
defects up to 2 cm2 with fibrin used to adhere the allograft in place.
Similar to osteochondral allograft transfer, this procedure benefits234from removing the possibility of donor site morbidity that comes
from an autologous tissue transfer procedure.51 PJAC treatment has
been reported to produce articular cartilage, which is more akin to
native tissue.50 Aldawsari et al. (2021), found that of the published
10 studies of PJAC radiological and clinical outcomes included in
their systematic review, PJAC demonstrated promising functional
outcomes, with MRIs demonstrating some filling of the OLTs.52
However, there was some disparity in cartilage repair between
studies and a consistent lack of repair in the subchondral bone and
subchondral lamina.52 Furthermore, a comparative study found
PJAC had no advantage over microfracture based on patient re-
ported outcomes.53
Cell-based surgical interventions are regenerative medicine
methods used to biologically regenerate the cartilage rather than
replace it. Techniques include autologous chondrocyte implanta-
tion (ACI), autologous matrix-induced chondrogenesis (AMIC),
platelet-rich plasma (PRP) and bone-marrow aspirate concentrate
(BMAC). These treatment modalities are often used following a
failed microfracture.54 ACI is a long-established 2-stage procedure
initially developed for chondral/osteochondral lesions in the
knee,55 that, in the ankle, involves harvesting macroscopically
normal hyaline cartilage either from the anterior talus or detached
osteochondral fragments.56,57 Previously, harvests for ankle ACI
have been obtained from the knee, with limited donor-site
morbidity.58,59 Chondrocytes are enzymatically extracted from
the cartilage and culture-expanded in vitro prior to being re-
implanted into the defect some 3e4 weeks later, beneath either a
periosteal patch or a commercially available type I/III collagen
patch.60 Alternatively, extracted chondrocytes can be cultured
directly on the collagen patch, a procedure known as matrix-
assisted ACI, or MACI. Pagliazzi et al. (2018) demonstrated a sig-
nificant improvement in the patient AOFAS score at 7 years
(87.2 ± 14.5 months) following the ACI.61 Despite the recent tech-
nical appraisal by the National Institute for Clinical Excellence
(NICE) approving the use of ACI in the knee,62 the same cannot be
said for the ankle. Current guidelines state that ACI will not be
routinely commissioned due to lack of evidence of the clinical
effectiveness of this therapy in the ankle, so it remains a clinical
trial/efficacy study line of treatment only at present (within the UK
at least).
To eradicate the need for a 2-stage procedure, the AMIC tech-
nique offers a promising, cost-effective alternative that was origi-
nally developed for the treatment of defects in the knee.63 The
technique consists of performing a microfracture followed by
securing a commercially available type I/III collagen patch over the
defect with the aim of not only trapping any MSCs entering the
defect area through the bleeding process, but also providing a
scaffold onwhich the cells may adhere and proliferate.64 It has been
suggested that transforming growth factor beta (TGF-beta) present
in the fibrin glue used to adhere the patch may enhance MSC
chondrogenic differentiation.65 However, a recent systematic re-
view of AMIC in the talus concluded that more clinical studies are
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Complete defect filling was demonstrated in 88% of patients
(n ¼ 33) treated with AMIC when assessed by MRI, along with
reduction in pain and improvement in function at 4.7 (mean; range,
2.3e8.0) years post-operatively.67 A systematic review of 13 papers,
further confirmed the efficacy of AMIC,66 as did another of 15
studies with outcomes up to five years post-operatively.68
There has been increasing interest in recent years with regards
to a biological therapy for OLTs utilising PRP, either autologous or
allogenic, which can either be administered directly to the lesion or
via intra-articular injection.69,70 PRP is rich in various growth fac-
tors and cytokines such as TGF-beta, platelet-derived growth factor
(PDGF), insulin-like growth factor (IGF) I and II, fibroblast growth
factor (FGF) and vascular endothelial growth factor (VEGF) which
are believed to enhance the natural healing response by promoting
MSC differentiation and cartilage formation.71e73 The use of PRP to
treat OLTs has also been systematically reviewed and was
concluded to result in significantly reduced pain and improved
function in comparison with microfracture alone.73 Despite being a
promising treatment option, to date, there is limited clinical evi-
dence for the use of PRP and an absence of a standardised prepa-
ration technique prior to application.74
BMAC is a type of biological adjuvant used for one-step cartilage
repair of OLTs, in the most recent decade.75 BMAC consists of
different types of stem cells and progenitor cells such as MSCs and
haematopoietic progenitor cells (HPCs), which have the potential to
repair injured hyaline cartilage. BMAC also contains an abundance
of growth factors and cytokines which may contribute to the
cartilage regeneration process.76 In BMAC therapy, bone marrow
aspirate is collected from the patient’s iliac crest, the white cells in
the marrow including MSCs, HPCs and all other immune cell frac-
tions are concentrated with the aid of commercial kits, and injected
directly into the patient’s OLT, combined with a biological scaffold,
such as a hyaluronic acid and fibrin gel.77 Unlike the two-stage
procedure of ACI, BMAC therapy can be achieved during a single
surgical operation, and does not require in vitro cell culture, which
significantly lowers the financial burden (as BMAC is not consid-
ered an advanced therapy medicinal product by regulators), and
avoids the heterogeneity caused by inconsistent cell culture pro-
tocols between laboratories. However, BMAC therapy still lacks
standardisation; there is no defined protocol for bone marrow
aspirate collection and concentration, and the scaffolds used in the
treatment vary.
BMAC has been demonstrated to have good long-term results in
the treatment of both OLTs and OA.77e79 In one of these studies
patients receiving BMAC therapy demonstrated significantly
increased AOFAS scores, decreased Ankle Osteoarthritis Scale (AOS)
pain and disability subscales and high patient satisfaction after 24
months and 10 year follow-up.77 Interestingly, two studies both
reported that the AOFAS score increased greatly in the first 24
months post-operatively, but after 48 months the AOFAS score was
slightly decreased, yet remained significantly higher than the pre-
operative score.77,78 The reason behind this still needs further
investigation.
5. Conclusion
In conclusion, there are several conservative and surgical ap-
proaches currently used to treat OLTs. All of these procedures have
pros- and cons- and a decision has to bemade based upon the likely
efficacy compared with the potential risks e.g. donor site morbidity
or risks associated with multiple surgical procedures. The judge-
ment of which approach is most suited to each patient depends on
the specific presentation of the defect e.g. size, site (contained or
uncontained) depth and cyst presence. Moreover, for certain235demographics of patient there will be greater impetus on choosing
an approach which will allow for rapid return to normal physical
activity, such as athletes. There remains a need to better predict
which procedure is most likely to benefit an individual, perhaps
through the use of imaging or fluid biomarkers, to ensure that
repair of OLTs can be achieved as quickly as possible preventing
further damage to the joint and the likelihood of developing OA.
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